Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience

about

Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience

Item

http://www.wikidata.org/entity/Q35742173

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Reduced administration of rasb ...... single-institution experience

@ast

Reduced administration of rasb ...... single-institution experience

@en

type

Item

label

Reduced administration of rasb ...... single-institution experience

@ast

Reduced administration of rasb ...... single-institution experience

@en

prefLabel

Reduced administration of rasb ...... single-institution experience

@ast

Reduced administration of rasb ...... single-institution experience

@en

P1476

Reduced administration of rasb ...... single-institution experience

@en

P2093

Akira Yoshida

http://www.w3.org/2001/XMLSchema#string

Hiromichi Iwasaki

http://www.w3.org/2001/XMLSchema#string

Katsunori Tai

http://www.w3.org/2001/XMLSchema#string

Mihoko Takai

http://www.w3.org/2001/XMLSchema#string

Satoshi Ikegaya

http://www.w3.org/2001/XMLSchema#string

Shinji Kishi

http://www.w3.org/2001/XMLSchema#string

Takahiro Yamauchi

http://www.w3.org/2001/XMLSchema#string

Takanori Ueda

http://www.w3.org/2001/XMLSchema#string

Yasufumi Matsuda

http://www.w3.org/2001/XMLSchema#string

Yoshimasa Urasaki

http://www.w3.org/2001/XMLSchema#string

P2860

Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer

The tumor lysis syndrome

Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout

Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.

Tumour lysis syndrome: new therapeutic strategies and classification.

Onco-nephrology: tumor lysis syndrome.

Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.

Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.

Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study

P304

2119-2125

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2015.3009

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276558028

http://www.w3.org/2001/XMLSchema#string

P698

26137024

http://www.w3.org/2001/XMLSchema#string

P932

4467316

http://www.w3.org/2001/XMLSchema#string